Targeted Temperature Management and Multimodality Monitoring of Comatose Patients After Cardiac Arrest

Peggy L. Nguyen, Laith Alreshaid, Roy A. Poblete*, Geoffrey Konye, Jonathan Marehbian and Gene Sung

Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States

Out-of-hospital cardiac arrest (CA) remains a leading cause of sudden morbidity and mortality; however, outcomes have continued to improve in the era of targeted temperature management (TTM). In this review, we highlight the clinical use of TTM, and provide an updated summary of multimodality monitoring possible in a modern ICU. TTM is neuroprotective for survivors of CA by inhibiting multiple pathophysiologic processes caused by anoxic brain injury, with a final common pathway of neuronal death. Current guidelines recommend the use of TTM for out-of-hospital CA survivors who present with a shockable rhythm. Further studies are being completed to determine the optimal timing, depth and duration of hypothermia to optimize patient outcomes. Although a multidisciplinary approach is necessary in the CA population, neurologists and neurointensivists are central in selecting TTM candidates and guiding patient care and prognostic evaluation. Established prognostic tools include clinical exam, SSEP, EEG and MR imaging, while functional MRI and invasive monitoring is not validated to improve outcomes in CA or aid in prognosis. We recommend that an evidence-based TTM and prognostication algorithm be locally implemented, based on each institution’s resources and limitations. Given the high incidence of CA and difficulty in predicting outcomes, further study is urgently needed to determine the utility of more recent multimodality devices and studies.

Keywords: cardiac arrest, targeted temperature management, anoxic brain injury, EEG, prognosis, multimodality monitoring

INTRODUCTION

Out-of-hospital cardiac arrest (CA) remains a leading cause of sudden morbidity and mortality. Based on recently published statistics from the American Heart Association, 1 of every 7.4 people in the United States will die of sudden cardiac death; however, in those who survive, outcomes have continued to improve over time (1). Enhanced recovery in CA-survivors is likely a product of multifactorial system-based changes, including the advent and evolution of targeted temperature management (TTM).

A multidisciplinary approach is necessary in the care of this complex and critically-ill population. Patients are managed by a team of physicians, nurses and ancillary staff. Neurologists and neurointensivists are often instrumental in the selection of TTM candidates and are central...
to patient care and prognostication. Early consultation with neurologists might increase the use of therapeutic hypothermia (TH) (2). Despite advances in the medical management of out-of-hospital CA, predicting outcomes remains a challenging task. Established prognostic tools have needed to be re-visited with the advent of TTM (3), and the literature has been limited by heterogeneous definitions, non-standardized study methods, small sample sizes, and publication bias. We therefore completed this review to highlight the clinical use of TTM, and to provide an updated summary of multi-modality monitoring and prognostication following CA in a modern neuroscience intensive care unit (ICU). Given the neuroprotective effect of TTM and its impact on prognostication, being familiar with current guidelines and literature is crucial to optimizing patient care.

PATHOPHYSIOLOGY OF ANOXIC INJURY FOLLOWING CARDIAC ARREST

Hypoxic-ischemic encephalopathy remains a primarily clinical diagnosis; however, the molecular pathophysiology has been studied in both animal and human models. Post-cardiac arrest syndrome, a term used to describe the resuscitative phase that follows return of spontaneous circulation (ROSC), encompasses four key processes: post-CA brain injury, post-CA myocardial dysfunction, systemic ischemia and reperfusion injury and a persistent precipitating pathology (4). Brain injury in the post-CA period is thought to be mediated by multiple pathways that result in ischemic injury, impaired cerebral autoregulation, and the development of diffuse cerebral edema (4).

During CA, the brain is exquisitely sensitive to global ischemia. Neuronal injury occurs when the severity and duration of ischemia is sufficient to cause depolarization of the neuronal plasma membrane. In animal models, this has been demonstrated to occur when blood flow falls below 10 mL/100 g per minute (5, 6). Animal studies have also demonstrated that loss of consciousness is experienced as early as 10 s following circulatory arrest, while an electroencephalogram (EEG) demonstrates isoelectric activity as early as 20 s after the event (7). When ischemic depolarization is brief with subsequent reperfusion, permanent glial injury may not occur; however, when the depolarization is more prolonged, a cascade of metabolic changes mediated by alterations in adenosine triphosphate (ATP), neurotransmitter pathways, mitochondrial dysfunction and calcium homeostasis occurs, which may lead to irreversible neuronal death. Ischemic depolarization >30 min most likely results in neuronal cell death regardless of reperfusion (5).

The exact mechanisms underlying ischemic injury following CA are poorly understood but are likely to involve multiple signaling pathways leading to disruption of cellular homeostasis. At a molecular level, global ischemia causes a depletion of intracellular ATP, with subsequent failure of ATP-dependent ionic channels. This results in accumulation of interstitial potassium with subsequent cell membrane depolarization. The eventual influx of sodium, chloride, and water into cells forms the basis of cytotoxic edema, which occurs during CA and other neurologic injuries. In addition, membrane depolarization results in the intracellular accumulation of calcium with activation of voltage gated calcium channels, as well as release of excitatory amino acid transmitters such as glutamate, perpetuating calcium and sodium influx into the neuron (5, 8).

If global ischemia occurs without subsequent reperfusion, failure of ATP production will lead to a final common pathway of cellular necrosis. Disruption of calcium homeostasis is thought to be one of the primary mechanisms of neuronal cell injury (9). Accumulation of calcium ions in the mitochondria increases free radical production and mitochondrial permeability transition (MPT), resulting in mitochondrial swelling, oxidative damage, loss of ATP production, and cell death. Cellular accumulation of calcium in the cytosol additionally triggers lipolysis, membrane destabilization, proteolysis, nitric oxide production, and endonuclease DNA degradation (5, 8). In vivo measurements of calcium demonstrate that in the acute ischemic period, cytosolic levels increase exponentially within 8 min of ischemia in vulnerable brain regions, although levels can return to baseline within 30–60 min if reperfusion occurs (5, 10).

In the setting of ROSC with cerebral reperfusion, additional ischemic injury can still occur. In particularly vulnerable neuronal subpopulations, including in the cortex, hippocampus, cerebellum, corpus striatum, and thalamus, degeneration can occur over hours to days (4). Secondary neuronal death is also mediated by disruption in calcium homeostasis, as levels of cytosolic calcium have been shown to increase up to 24 h after the primary insult in susceptible brain regions (5). Additional inflammatory processes involving cytokines are implicated in peripheral tissue ischemia. Cytokines such as interleukin-6 (IL-6) and tumor necrosis factors (TNF) perpetuate delayed ischemia in the reperfusion period. Animal models have demonstrated that rapid infiltration of neutrophil and pro-inflammatory T-lymphocytes into the brain occur as early as 3 h following ROSC, and last up to 3 days (11).

A PARADIGM SHIFT: TARGETED TEMPERATURE MANAGEMENT IN THE MODERN ICU

For the last two decades, TTM, previously referred to as therapeutic hypothermia, has been a growing research topic in the ICU literature. Currently, given its neuroprotective role after CA with improvement of neurologic outcomes, TTM is considered the standard of care for survivors of CA who present with coma after ROSC (12).

Mechanisms of Neuroprotection With Hypothermia

The manner that hypothermia acts as a neuroprotectant is still not fully understood. In animal models, hypothermia has been shown to limit several microscopic events, including the inhibition of inflammatory cytokine release (ex. interleukins, prostaglandins), that normally lead to apoptosis and cell death.
(13–15). At a tissue level, hypothermia was found to reduce cerebral metabolic demand (approximately 6–8% per 1°C), cerebral edema, and intracranial pressure (ICP), while also increasing seizure threshold (16).

**Targeted Temperature Management**

TTM was first introduced in the 1950s and 1960s, primarily in animal models. Many of these early studies showed that both moderate systemic hypothermia (32–36°C) (17) and mild hypothermia (34°C) (18–20) cause decreased brain damage after CA in animals. The subject of TH somewhat faded until it was reintroduced in human subjects in the early 2000s by two important randomized trials (RCTs): a study by Bernard et al., and the Hypothermia after Cardiac Arrest Study Group (21, 22). These studies were the first to provide Class I evidence supporting the use of TTM for CA survivors to improve both survival and functional outcomes using mild hypothermia (32–34°C for 12 or 24 h). Based on these findings, the International Liaison Committee on Resuscitation (ILCOR) recommended in 2003 that CA-survivors in coma should receive TH when the initial rhythm was ventricular fibrillation, with potential benefit with other rhythms (23).

These recommendations have since been under continuous review and change. Three major clinical trials and a meta-analysis by Kim et al. failed to show definitive improvement in outcomes in patients with non-shockable rhythm (24–27). Similarly, TTM does not appear to benefit patients who sustain in-hospital CA in terms of mortality or neurologic recovery (28). Regarding the timing and duration of TTM and depth of TH, best practices are unknown. Pre-hospital initiation of TTM has not been shown to improve outcomes (29, 30). Prolonged cooling also appears to have no important clinical effect, Kirkegaard et al. compared 24 vs. 48 h of cooling to 33°C and found no significant differences in neurologic outcomes (31). While early guidelines recommend mild hypothermia, a recent RCT found no change in neurologic recovery or survival at 6 months when comparing 33° and 36°C (32).

Current guidelines do not recommend a specific cooling method for TTM; however, multiple methods are available for induction and maintenance, including both invasive and non-invasive devices (33, 34). Recent data suggest that endovascular cooling is more rapid and may be more effective in maintaining TTM, although surface cooling may be as effective during induction (35, 36); however, clinical trials to-date have not shown effect on overall mortality and neuro-sequelae between invasive and non-invasive methods. Alternative devices, including transnasal, peritoneal and esophageal cooling are under investigation, but no recommendations for their use can be made currently (37–39).

The current American Heart Association, Canadian TTM guidelines, and American Academy of Neurology practice parameters are considered the most evidence-based clinical recommendations and the standard of care for managing post-CA patients who remain in coma after ROSC (12, 40, 41) (Table 1). Further research is needed to study different aspects of these guidelines to achieve the best clinical results.

**TABLE 1 | Summary of recent guidelines on targeted temperature management for out-of-hospital cardiac arrest patients.**

| Committee | Summary of recommendations |
|-----------|-----------------------------|
| 2015 American Heart Association (12) | • Induce hypothermia for unconscious adult patients with ROSC after OHCA when the initial rhythm was VF or pVT (class I, level of evidence: B–R) • Similar therapy may be beneficial for patients with non-VF/non-pVT (non-shockable) OHCA or with in-hospital arrest (class I, level of evidence: C–EO) • The temperature should be maintained between 32°–36°C (class I, level of evidence: B–R) • It is reasonable to maintain TTM for at least 24 h (class IIa, level of evidence: C–EO) • Routine prehospital cooling of patients with ROSC with IV rapid infusion is not advised (class III; no benefit; level of evidence A) • It is reasonable to prevent fever in comatose patients after TTM (class IIb, level of evidence C–LD) • Hemodynamically stable patients with spontaneous mild hypothermia (i.e., 33°C) after resuscitation from cardiac arrest should not be actively rewarmed • We recommend that patients who suffer out-of-hospital cardiac arrest are eligible for TTM (High quality, strong recommendation) • We recommend that TTM can be initiated in any medical environment with the available supports, including prehospital, ED and critical care unit (Moderate quality, strong recommendation) • We recommend that clinicians attempt to achieve target temperature as rapidly as possible (Low quality but strong recommendation) • We do not recommend a specific cooling method for TTM. • We recommend that patients undergoing TTM should receive sedation and analgesia • We suggest that paralytics be used during induction and rewarming phases of TTM, to facilitate tight temperature control and to prevent shivering • Comatose patients after CA in whom the initial cardiac rhythm is VT or VF, TH is likely effective in improving neurologic outcome and survival (Level A) • Comatose patients after CA in whom the initial cardiac rhythm is VT/VF or PEA/asystole should not be offered prehospital cooling with 2 liters 4°C IV fluid or intranasal cooling (Level A) • Comatose patients after CA in whom the initial cardiac rhythm is either VT/VF or PEA/asystole, TTM (33°C for 24 h followed by 8 h of rewarming to 37°C and maintained below 37.5°C until 72 h) is likely as effective as TH in improving neurologic outcome and survival and is an acceptable alternative to TH (Level B) • In comatose patients after CA, the addition of coenzyme Q10 to TH possibly improves survival but does not improve neurologic status at 3 months and may be offered (Level C) • No recommendations are made on the following (Level U): Use of epoetin alfa in addition to mild TH |
| 2016 Joint Statement from The Canadian Association of Emergency Physicians, the Canadian Critical Care Society, Canadian Neurocritical Care Society, and the Canadian Critical Care Trials Group (40) | Use of standardized protocols for TH Use of endovascular cooling instead of surface cooling Use of standardized protocols for TH Use of epoetin alfa in addition to mild TH |
| 2017 American Academy of Neurology Practice Guidelines (41) | Use of coenzyme Q10 in addition to moderate hypothermia (35°C) Use of a single-lumen IVC catheter Use of invasive cooling instead of surface cooling Use of endovascular cooling instead of surface cooling |

ROSC, return of spontaneous circulation; OHCA, out-of-hospital cardiac arrest; VF, ventricular fibrillation; pVT, pulseless ventricular tachycardia; IV, intravenous; TTM, targeted temperature management; R, randomized; EO, expert opinion; LD, limited data; VT, ventricular tachycardia; TH, therapeutic hypothermia; PEA, pulseless electrical activity; IV, intravenous.
NEUROPHYSIOLOGIC TESTING AFTER CARDIAC ARREST

Use of EEG Studies
Beyond the clinical exam, EEG is one of the most widely used prognostic tools after anoxic brain injury from CA. Areas most susceptible to hypoxic-ischemic injury, including the cerebral cortex and hippocampus (42) are highly epileptogenic and are feasibly captured by surface EEG. From a practical aspect, it is an attractive study because it is non-invasive, can be performed rapidly, and is available at most hospitals managing CA patients. Clinical seizures are reported from TTM trials to occur in over 25% of patients (32), while malignant EEG features are recorded in up to 86% of patients who remain comatose after resuscitation and re-warming (43). Non-convulsive seizures are thought to occur in approximately one-quarter of comatose patients after cardiac arrest (44, 45).

Timing and Duration of EEG
The optimal timing for EEG recording after CA is unknown. Since sedation is required for TH and TTM, EEG is often reserved for those who fail to awake after rewarming; however, early monitoring may be indicated. In study populations undergoing TTM, most seizures on continuous EEG (cEEG) occur within 12 h of resuscitation and prior to achieving normothermia (44, 45). Malignant patterns in the first 8 h of cEEG have also demonstrated a high positive predictive value for poor outcome (46). Although this suggests utility in early cEEG, studies have shown that intermittent short-duration EEG has potentially similar diagnostic and prognostic yield, with no difference in clinical outcomes, and is associated with reduced per patient cost (47, 48). Given the lack of evidence to suggest treatment of seizures and malignant EEG findings improves outcomes (49, 50), the principal use of intermittent EEG as a prognostic tool is reasonable in centers where cEEG is not readily available.

Prognostic Value of EEG Findings
Electroencephalogram findings most thought to predict poor neurologic outcome includes absence of EEG reactivity, alpha coma, low-voltage recording, burst-suppression pattern, and status epilepticus (49). Several older and newer grading scales that account for TTM have been proposed to classify EEG findings after CA (50–54); however, none have achieved widespread adoption. This may in part be due to a difficulty of interpreting and understanding the clinical implications of complex EEG findings for non-electroencephalographers. A simplified system might differentiate between “benign” and “malignant” EEG patterns (43, 55).

EEG features in patients who do not undergo therapeutic hypothermia
A low-voltage EEG (≤21 µV) reflects neuronal dysfunction and is a reliable predictor of poor outcome in those who do not receive TTM. In two larger studies, low-voltage EEG seen at 24–72 h after resuscitation was associated with poor outcome with a 0% false positive rate (FPR) (56, 57). Similarly, myoclonic status epilepticus (MSE) when differentiated from a benign form of chronic myoclonus, Lance-Adams syndrome, has been invariably associated with poor outcome in those who are not treated with TH (58). Although electrographic seizure other than MSE, alpha coma and burst suppression are considered useful prognostic findings, they are not invariably associated with poor outcome in the CA population (53, 57, 59, 60).

EEG features in patients treated with therapeutic hypothermia.
TTM improves neurologic outcomes following CA (32) but lowering intracranial temperature and the sedation necessary for TH confounds EEG interpretation. Its accuracy as a prognostic tool has had to be re-evaluated with the advent of TTM. Although early post-hypoxic myoclonus is associated with poor prognosis, since the publication of the 2006 American Academy of Neurology Guidelines on prognostication following CA (61), several authors have reported outcomes better than predicted in patients with myoclonic seizures (44, 50, 62–65). Cortical myoclonus or status myoclonus within 72 h from CA did not exclude a good neurologic recovery defined as Cerebral Performance Category (CPC) 1 or 2, with a 5% FPR (44, 50, 62–64). Some have suggested that “benign” and “malignant” myoclonus or MSE can be differentiated by the background EEG pattern (65, 66).

Status epilepticus (SE) other than MSE strongly predicts poor outcome (CPC 3–5) (45, 50, 67); however, good outcome in CA patients is possible. In one study of 106 comatose CA survivors, 2/33 SE patients achieved good neurologic outcomes (66). Like MSE, EEG background is an important factor. In a study of cEEG in TTM patients, those with SE arising from burst-suppression invariably had poor neurologic recovery, while good outcomes were possible in those with SE arising from an EEG with continuous background (4% FPR) (68).

A burst-suppression EEG background or low-amplitude recording alone does not predict poor outcome with 100% specificity (64, 68, 69). Similarly, a non-reactive EEG background is compatible with neurologic recovery with a 3% FPR when recorded during TH (50, 62, 67), while in one larger study, three patients with absence of EEG reactivity within 72 h of resuscitation achieved good outcomes (63). Although prognosis is not invariably poor in patients undergoing TTM with a single malignant EEG feature, the presence of multiple features significantly increases the likelihood of poor outcome. In a large cohort of patients enrolled in a TTM trial, a single malignant EEG feature had a low specificity for poor prognosis (48%), which increased to a 96% positive predictive value when two malignant EEG features were present (43).

Continuous EEG Using Depth Electrodes
In neurocritical care, EEG depth electrodes are inserted through small burr holes, often in combination with other multimodality brain monitors to capture electrographic activity below the cortex. Their use in the management and prognosis of CA survivors has not been extensively studied in any large trial. In one case report, authors demonstrated the feasibility of using multimodality monitoring, including depth EEG, to detect SE that was associated with reductions in brain tissue oxygen tension.
and increase in cerebral blood flow and brain temperature (70). Future study is needed if invasive monitoring that includes depth EEG has additional prognostic value in CA.

Limitations
Beyond being confounded by hypothermia and sedative medications, EEG for prognostication after CA has other important limitations. The frequency of EEG and availability of cEEG is dependent on institutional resources and varies widely, with cEEG often only available at larger academic centers. Given the lack of evidence suggesting its superiority to intermittent EEG (49, 50), the American Clinical Neurophysiology Society and other committees have not made guidelines to standardize EEG after CA (71, 72).

EEG interpretation remains a specialized skill, with the large proportion of ICU providers unable to independently interpret studies. Recordings and terminology can be confusing to non-epileptologists. Even among experts, interrater agreement on EEG patterns can vary (73), resulting in many authors proposing standardization to classifying EEG in this population (43, 73). Use of automated, quantitative EEG techniques may find future utility in prognostication and is the subject of current study (51, 74, 75).

Somatosensory Evoked Potentials
Somatosensory Evoked Potentials (SSEPs) are often used for prognostication in CA survivors who have a poor neurologic exam after resuscitation and normothermia (76). In the most widely used test, small electrical stimulation (<50 µV) is applied to the median nerve in the arm, followed by recording of post-stimuli waveforms over the primary somatosensory cortex by surface electrodes (76). The bilateral absence of the short-latency N20 waveform is highly specific for poor outcome after CA. In those who are not treated with TH, bilateral absence of the N20 response within the first 7 days showed a 0% FPR (95% CI 0–12] with only 1/432 patients achieving a good outcome (58). In TTM patients, this finding also showed high predictive value for poor outcome both during TH (64, 77, 78) and after rewarming (62, 64, 67, 77, 78), with exception of one case where reappearance of the N20 response corresponded with full neurologic recovery (79). Given these robust findings, early use of short-latency N20 SSEPs for prognostication after CA is endorsed by multiple expert committees (64, 72). The use of longer latency waveforms, such as the N70 response (80), requires further study.

Limitations
The optimal timing for SSEP is unknown. Given both peripheral and central conduction times are prolonged during hypothermia (81), most practitioners delay SSEP testing until after the rewarming phase. Using a dichotomous measure of absent vs. present SSEP also significantly limits its sensitivity in predicting poor outcomes. Determining prognostically useful N20 amplitude thresholds should be further studied in future cohorts (82). Importantly, SSEPs are not routinely performed at all hospitals that treat CA survivors, further limiting its adoption in standardized prognostication algorithms.

IMAGING MODALITIES AFTER CARDIAC ARREST

CT Imaging
Brain CT is typically the first neuroimaging study obtained in out-of-hospital CA survivors, as it can be performed quickly and identifies patients who may not benefit from TTM. The primary finding in moderate to severe hypoxic-ischemic injury is cerebral edema characterized by attenuation of affected gray and white matter (83). In a study of TTM trial patients, generalized edema was seen in 9.6% of CT images within 24 h of ROSC and predicted poor outcome (CPC 3–5) with 97.6% specificity (95% CI 91.8–9.4) but only 14.4% sensitivity (95% CI 9.4–21.4) (84). Between days 1 and 7, generalized cerebral edema predicted poor outcome with a 0% FPR. In this study, other CT findings were infarct in 18.9% and intracranial hemorrhage in 6.3% (84).

The Role of Standard MRI
Despite MRI being more sensitive for detecting neuronal injury compared to CT, because of longer acquisition times and more necessary resources, its early use during the pre-TH and TH phase is limited. The optimal time window for MRI imaging is unknown; however, prognostic accuracy may be greatest between 2 and 5 days, with reduced sensitivity if done within 24 h (85, 86).

Brain areas most susceptible to hypoxic-anoxic injury include the cerebral cortex and deep brain nuclei that include the caudate, basal ganglia and thalamus. Diffusion restriction involving these areas, characterized by hyperintensity on diffusion-weighted imaging (DWI) and hypointensity on apparent diffusion coefficient (ADC) images, predicts poor outcome with high specificity (85, 87, 88). In a study correlating MRI findings with neuron-specific enolase, a biomarker with high prognostic value, levels >33 µg/ml after CA was associated with extensive DWI changes in both deep nuclei and the cortex (89). These patients had invariably poor outcome. More recently, quantitative measures of diffusion restriction burden on MRI has been proposed to standardize post-CA prognostication (86, 87, 90, 91); however, the most appropriate thresholds have not been established. In one multi-centered study, an ADC value <650 × 10−4 m²/s in ≥10% of the total brain volume independently predicted poor outcome with a specificity of 91% (95% CI 75–98) and sensitivity of 72% (95% CI 61–80), with >22% of brain volume needed to achieve 100% specificity (90). In another study, <15% total brain volume with significant diffusion restriction was predictive of good neurologic recovery (91). As part of multimodality monitoring, combining MRI findings with EEG features, biomarkers and clinical exam may result in the highest accuracy in predicting outcomes (89, 91). Currently, the implementation of MRI in post-CA prognostication algorithms has not been strongly recommended by consensus guidelines (72).

Other Imaging Modalities

Functional Imaging
There are a limited number of studies with small sample sizes that have investigated the use of functional MR imaging (fMRI) in the management and prognosis of CA survivors (92). In a positron
emission tomography (PET) pilot study of 7 post-CA patients, all initially demonstrated a low cerebral metabolic rate of oxygen metabolism (CMR02) and cerebral blood flow; however, at day 7, those with persistent coma had lower CMR02 compared to those who regained consciousness (93). More recently, fMRI connectome imaging has demonstrated potential as a prognostic tool in CA, where patients who achieved favorable outcome have higher default-mode network connectivity (94, 95). It is unclear if fMRI is more accurate in predicting outcome in comparison to other MRI modalities (94), and they have not been compared directly with more established prognostic tools (92). Validation of PET imaging and other fMRI techniques may be a field of future research.

### Transcranial Doppler Ultrasound

Transcranial Doppler ultrasound (TCD) is a useful bedside, non-invasive tool for monitoring characteristics in cerebral blood flow and intracranial vascular resistance. Early TCD studies suggested that higher vascular resistance indices and post-resuscitation hyperemia predicted poor outcome (96, 97); however, subsequent larger studies have not found correlation between TCD measurements and outcomes during both the TH phase and after rewarming (98, 99). TCDs in CA survivors is not part of routine practice in most hospital centers.

### Near-Infrared Spectroscopy

NIRS is a non-invasive method of monitoring regional oxygenation in the cerebral cortex ($rSO_2$). Near-infrared light emitted by one surface probe passing through the cortex is absorbed by biological molecules including oxyhemoglobin, deoxyhemoglobin, and less commonly cytochrome-c oxidase (CCO), at different wavelengths. Differences in absorption by the receiving probe are used to quantify the proportion of oxygenated hemoglobin or other molecule, which is reflective of perfusion (101). Advantages of NIRS are that it is non-invasive and can be performed at bedside.

Higher values of $rSO_2$ on NIRS have been demonstrated in patients achieving ROSC compared to those who do not achieve ROSC (106). Studies have also demonstrated higher values of $rSO_2$ using NIRS in post-CA patients with good neurologic outcome, although specific thresholds or cut-offs have not been established. In one study, post-CA patients with good neurologic outcome had higher $rSO_2$ values compared to those who with poor outcome (55.6 ± 20.8% vs. 19.7 ± 11.0%, p < 0.001, respectively), with a threshold $rSO_2$ value of >42% for predicting good outcome yielding a sensitivity of 0.79, specificity of 0.95, PPV 0.41 and NPV 0.99 (107). In comparison, another prospective study found that although post-CA patients with a good outcome had significantly higher median $rSO_2$ levels compared to those who had poor outcome (median $rSO_2$ of 68% vs. median $rSO_2$ of 58%, respectively) there was significant overlap in the range of $rSO_2$ between the two groups, limiting its use as a prognostic tool (108).

### Microdialysis Catheters

Microdialysis catheters allow frequent assessments of cerebral metabolism and ischemic injury by utilizing a thin dialysis probe that is inserted into brain interstitial tissue. The catheter can measure extracellular solutes that diffuse through the membrane of the probe. Measurable solutes include markers of cerebral metabolism such as CSF lactate, pyruvate, glucose, and markers of excitotoxicity such as glutamate, and cellular damage such as glycerol (109, 110). Additional values of importance, including
markers of metabolic crisis such as lactate:pyruvate ratio (LPR), can be calculated autonomously.

During CA, the brain becomes oligemic, leading to diffuse ischemia. Patterns of ischemia are characterized by a decrease in cerebral glucose and an increase in cerebral lactate, which may reflect a state of anaerobic metabolism. These findings, along with increased glutamate and LPR have been demonstrated in animal models of CA (111, 112). Microdialysis results may have additional prognostic value. In rats, survivors of CA after CPR showed significantly higher cerebral lactate and glucose concentrations within 8 min compared to non-survivors, as well as increased lactate, glucose and pyruvate beyond 8 min (111). One small patient series of 4 human subjects with microdialysis catheters who underwent TTM demonstrated elevated LPRs that persisted despite achieving a neurologically intact exam (113). Although glutamate was initially high, values normalized in all 4 patients. Another patient series of CA survivors who underwent TTM found that LPRs progressively increased in those with poor outcomes with significantly higher values on days 2–3 compared to patients with favorable outcomes (114).

These preliminary studies establish the feasibility of microdialysis catheter monitoring in CA patients undergoing TTM. Although it has been demonstrated that neurochemical markers of cerebral ischemia are found after CA, further studies are needed to determine if they have a role in predicting outcome.

**Jugular Bulb Catheters**

Indirect measurements of cerebral oxygenation using jugular bulb catheters have been used in brain injured patients to assess the balance of cerebral oxygen supply and consumption, and to estimate cerebral perfusion (101). The catheters are placed in the internal jugular vein and are directed cranially to measure venous oxygen saturation (SjvO2), with a normal range of 55–70%. In CA, SjvO2 is reduced, reflecting decreased oxygen delivery and increased oxygen utilization in a stress state (101). Disadvantages of jugular bulb catheters are that it is an invasive monitor, with risk of carotid puncture, hematoma formation, or venous thrombosis during prolonged monitoring (101).

In a study of 30 comatose post-resuscitation patients, all subjects had an initial SjvO2 that was lower than the measured mixed venous oxygen saturation (SmvO2) within 6 h of CA, but in 12/20 non-survivors, SjvO2 increased significantly to values higher than the SmvO2 (115). The significance of this finding is unclear. Other studies have demonstrated higher SjvO2 in comatose non-survivors of CA, which was thought to reflect a decrease in cerebral oxygen consumption due to loss of functional brain tissue and may be an indicator of poor neurologic outcome (116). Although it involved a small sample size, the study found that the positive predictive value of a difference between SmvO2 and SjvO2 of < 0 for predicting irreversible brain damage at 24 h following CA was 93%, while the negative predictive value of SmvO2–SjvO2 > 0 was 53%. Another study of 34 patients found that having a SmvO2 > SjvO2 between 24 and 48 h after ROSC had a positive predictive value of 100% and a negative predictive value of 92% for predicting recovery of consciousness (117). Unfortunately, these results have not been reliably duplicated with TTM patients. In the TTM era, one study of 75 patients found no difference in SjvO2 between patients with good and poor outcome at 6 months (118).

**External Ventricular Drain and ICP Catheters**

ICP monitoring devices are typically categorized based on their location of placement, often either ventricular or intraparenchymal, with extradural and subdural monitors being less common. Intraparenchymal catheters are both diagnostic and therapeutic, allowing clinicians to drain cerebrospinal fluid if ICP rises. Intraparenchymal monitors have the advantage of lower infection rates compared to ventricular catheters; however, they are more prone to drift and technical complications that limit its usability (119).

Following CA, cerebral edema occurs as early as the first 24 h, with CT imaging demonstrating diffuse loss of gray-white differentiation in up to 12% of scans performed and global cerebral edema in as many as 6% (120). ICP monitoring is frequently used when cerebral edema is diagnosed in brain injured patients, including those with traumatic brain injury, intracerebral hemorrhage, or subarachnoid hemorrhage. Uncontrolled intracranial hypertension is associated with poor outcomes in the TBI literature, and although its impact in CA patients is not well defined, ICP elevations can result in cerebral herniation and may serve as a trigger for monitoring and augmenting cerebral perfusion pressures (CPP) (8).

Elevations in ICP have been identified in post-CA patients during the resuscitation period, which may be due to delayed hyperemia (97). In one post-resuscitation study of ICP monitoring performed on 84 patients, peak ICP > 25 mmHg was associated with poor outcomes. Additionally, non-survivors consistently had higher ICPs and lower CPP than survivors (121). This association has been noted in more recent studies following the advent of TTM. Increases in ICP have been noted during both TH and the rewarming period, and at least in one study, all cases of ICP > 25 mmHg were associated with mortality (113, 122). Even when CPP did not differ between groups, studies have shown elevated ICPs are associated with poor outcome (114). The evidence suggests that elevated ICP can occur after CA and during rewarming in patients who undergo TTM; although, to date, no large studies have used ICP monitors to guide management of the post-CA patient.

**DISCUSSING PROGNOSIS AFTER CARDIAC ARREST**

Despite the use of multiple prognostic tools, prediction of outcomes after CA is difficult. Registries such as the International Cardiac Arrest Registry (INTCAR), a prospective multinational registry of treatment and outcomes in post-CA patients who achieve ROSC, have been developed with the intention of furthering research on CA outcomes (123). The ongoing clinical trial, Multimodal Outcome Characterization in Comatose Cardiac Arrest Patients Registry and Tissue Repository (MOCHA), proposes to develop a multimodal prediction model for outcomes in post-CA patients (124). Currently, given the
available evidence in the literature, it is reasonable to discuss pertinent clinical exam, EEG, SSEP, biomarker, and CT and MRI findings with family members and surrogate decision makers to help guide their expectations and inform their decisions. Further validation is needed before fMRI and invasive multimodality monitoring devices are used in standardized prognostication algorithms.

The timing of outcome prediction is crucial in CA. The 72 h clinical exam remains the most informative; however, in patients receiving TTM, the earliest time for prognostication using the clinical exam may be 72 h after achieving normothermia and after other confounding factors, such as paralysis and sedation are safely excluded (12, 64). Similarly, the accuracy of other prognostic tools may be affected by TH, with MRI at day 2–5 being reasonable for prognostication (85, 86).

The accuracy and limitations of prognostication should be shared with all family members and decision makers. Caution must be taken to avoid propagation of a self-fulfilling prophecy in withdrawing life sustaining therapy in this patient population. Studies on prognostication post-CA may suffer from bias as patients with poor neurologic prognosticators may receive limited intensive care or may have had recommendations for withdrawal of treatment (125). Often, goals of care established by family members or decision makers do not align with a patient’s prognosis (126), where patient age, comorbidities, prior patient wishes, and cultural aspects factor in to a decision. Establishing and implementing a protocol and expected practice, based on each institution’s resources and limitations may help clinicians and families navigate this difficult course.

CONCLUSION

Neurologists and neurointensivists are central to guiding TTM, ICU care and prognostication in survivors of CA. Given the neuroprotective effects of TTM and their influence on prognostication and multimodality monitoring, providers should be familiar with the most recent guidelines and literature. We recommend that an evidence-based TTM and prognostication algorithm be locally implemented, based on each institution’s resources and limitations. Given the high incidence of CA and the difficulty in predicting outcomes, further study is urgently needed to determine the utility of more recent multimodality devices and studies.

AUTHOR CONTRIBUTIONS

RP, JM, and GS conceived the manuscript topic and outline. PN, LA, RP, and GK were the primary authors of the manuscript with input from all authors. PN, RP, and JM were involved in critical manuscript revisions. RP, JM, and GS directed manuscript preparation. All authors read and approved the submitted version.

REFERENCES

1. Benjamin EJ, Virani SS, Callaway CW, Chang AR, Cheng S, Chuve SE, et al. Heart disease and stroke statistics—2018 update: a report from the american heart association. Circulation (2018) 137:e67–492. doi: 10.1161/CIR.0000000000000538
2. Guterman EL, Kim AS, Josephson SA. Neurologic consultation and use of therapeutic hypothermia for cardiac arrest. Resuscitation (2017) 118:43–8. doi: 10.1016/j.resuscitation.2017.06.025
3. Samaniego EA, Persoon S, Wijman CAC. Prognosis after cardiac arrest and hypothermia: a new paradigm. Curr Neurol Neurosci Rep. (2011) 11:11–19. doi: 10.1007/s11910-010-0148-9
4. Neumar RW, Nolan JP, Adrie C, Aibiki M, Berg RA, Böttiger BW, et al. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication. A consensus statement from the International Liaison Committee on Resuscitation (American Heart Association, Australian and New Zealand Council on Resuscitation, European Resuscitation Council, Heart and Stroke Foundation of Canada, Inter-American Heart Foundation, Resuscitation Council of Asia, and the Resuscitation Council of Southern Africa); the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; and the Stroke Council. Circulation (2008) 118:2452–83. doi: 10.1161/CIRCULATIONAHA.108.190652
5. Neumar RW. Molecular mechanisms of ischemic neuronal injury. Ann Emerg Med. (2000) 36:483–506. doi: 10.1016/mem.2000.110995
6. Symon L. Flow thresholds in brain ischaemia and the effects of drugs. Br J Anaesth. (1985) 57:34–43. doi: 10.1093/bja/57.1.34
7. Hossmann KA, Grosse-Ophoff R. Recovery of monkey brain after prolonged ischemia. I. Electrophysiology and brain electrolytes. J Cereb Blood Flow Metab. (1986) 6:15–21. doi: 10.1038/jcbfm.1986.3
8. Reis C, Akyol O, Araujo C, Huang L, Enkhjargal B, Malaguit J, et al. Pathophysiology and the monitoring methods for cardiac arrest associated brain injury. Int J Mol Sci. (2017) 18:E1129. doi: 10.3390/ijms18011129
9. Deshpande JK, Siesjö BK, Wieloch T. Calcium accumulation and neuronal damage in the rat hippocampus following cerebral ischemia. J Cereb Blood Flow Metab. (1987) 7:89–95.
10. Erecinska M, Silver IA. Relationship between ions and energy metabolism: cerebral calcium movements during ischaemia and subsequent recovery. Can J Physiol Pharmacol. (1992) 70(Suppl.3):S190–3.
11. Deng G, Carter J, Traystman RJ, Wagner DH, Herson PS. Pro-inflammat ory T-lymphocytes rapidly infiltrate into the brain and contribute to neuronal injury following cardiac arrest and cardiopulmonary resuscitation. J Neuroimmunol. (2014) 274:132–40. doi: 10.1016/j.jneuroim.2014.07.009
12. Callaway CW, Donnino MW, Fink EL, Goyal M, Luchterhand CE, Kern KB, et al. Part 8: post-cardiac arrest care: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation (2015) 132(Suppl. 2):S465–82. doi: 10.1161/CIR.0000000000000262
13. Scott BD, Hogue T, Fixley MS, Adamson PB. Induced hypothermia following out-of-hospital cardiac arrest: initial experience in a community hospital. Clin Cardiol. (2006) 29:525–29. doi: 10.1002/clc.23
14. Alam HB, Bowyer MW, Koutouva E, Gushchin V, Anderson D, Stanton K, et al. Learning and memory is preserved after induced asanguineous hyperkalemic hypothermic arrest in a swine model of traumatic exsanguination. Surgery (2002) 132:728–88. doi: 10.1067/msy.2002.125787
15. Weng Y, Sun S. Therapeutic hypothermia after cardiac arrest in adults: mechanism of neuroprotection, phases of hypothermia, and methods of cooling. Crit Care Clin. (2012) 28:231–43. doi: 10.1016/j.ccc.2011.01.012
16. Sekhon MS, Ainslie PN, Griesdale DE. Clinical pathophysiology of hypoxic ischemic brain injury after cardiac arrest: a “two-hit” model. Crit Care (2017) 21:90. doi: 10.1186/s13054-017-1670-9
17. Leonov Y, Sterz F, Safar P, Radovsky A. Moderate hypothermia after cardiac arrest of 17 minutes in dogs: effect on cerebral and cardiac outcome. Stroke (1990) 21:1600–6. doi: 10.1161/01.STR.21.11.1600

18. Kuboyama K, Safar P, Radovsky A, Fisherman SA, Szczotkowski SW, Alexander H. Delay in cooling negates the beneficial effect of mild resuscitative cerebral hypothermia after cardiac arrest in dogs: a prospective, randomized study. Crit Care Med. (1993) 21:1348–54. doi: 10.1097/00003246-199309000-00119

19. Sterz F, Safar P, Fisherman SA, Radovsky A, Kuboyama K, Oku K. Mild hypothermic cardiopulmonary resuscitation improves outcome after prolonged cardiac arrest in dogs. Crit Care Med. (1991) 19:379–89. doi: 10.1097/00003246-199103000-00017

20. Weinrauch V, Safar P, Fisherman SA, Kuboyama K, Radovsky A. Beneficial effect of mild hypothermia and detrimental effect of deep hypothermia after cardiac arrest in dogs. Stroke (1992) 23:1454–62. doi: 10.1161/01.STR.23.10.1454

21. Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med (2002) 346:557–63. doi: 10.1056/NEJMoa0203289

22. Hypothermia After Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med (2002) 346:557–63. doi: 10.1056/NEJMoa0203289

23. Donnino MW, Andersen LW, Berg KM, Reynolds JC, Nolan JP, Morley, PT, et al. Temperature management after cardiac arrest: an advisory statement by the advanced life support task force of the international liaisons committee on resuscitation and the American Heart Association Emergency Cardiovascular Care Committee and the Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation. Circulation (2015) 132:2448–56. doi: 10.1161/CIRCULATIONAHA.114.011691

24. Testori C, Sterz F, Behringer W, Haugk M, Uray T, Zeiner A, et al. Outcome, timing and adverse events in therapeutic hypothermia after cardiac arrest of 17 minutes in dogs: effect on cerebral and cardiac outcome. J Med (2002) 30:1756. doi: 10.1056/NEJMoa012689

25. Vaahersalo J, Hiltunen P, Tiainen M, Oksanen T, Kaukonen KM, Kurola H. Delay in cooling negates the beneficial effect of mild resuscitative cerebral hypothermia after cardiac arrest in dogs. Acta Anaesthesiol Scand (2009) 53:926–34. doi: 10.1111/j.1399-6576.2009.02021.x

26. Mader TJ, Nathanson BH, Soares WE, Coute RA, McNally BF. Comparative effectiveness of therapeutic hypothermia after out-of-hospital cardiac arrest: insight from a large data registry. Ther Hypothermia Temp Manag. (2014) 4:21–31. doi: 10.1089/thr.2013.0018

27. Kim YM, Jeong SH, Klem ML, Callaway CW. Does therapeutic hypothermia improve outcomes after in-hospital cardiac arrest? A systematic review and meta-analysis of randomized and non-randomized studies. Resuscitation (2012) 83:188–96. doi: 10.1016/j.resuscitation.2011.07.031

28. Nichol G, Husztéi I, Kim F, Fly D, Parnia S, Donnino M, et al. Does induction of hypothermia improve outcomes after in-hospital cardiac arrest? Resuscitation (2013) 84:620–25. doi: 10.1016/j.resuscitation.2012.12.009

29. Nielsen N, Hovdenes J, Nilsson F, Rubertsson S, Stammet P, Sunde K, et al. Outcome, timing and adverse events in therapeutic hypothermia after out-of-hospital cardiac arrest. Acta Anaesthesiol Scand. (2009) 53:926–34. doi: 10.1111/j.1399-6576.2009.02021.x

30. Huang FY, Huang BT, Wang PJ, Zuo ZL, Heng Y, Xie TL, et al. The efficacy and safety of prehospital therapeutic hypothermia in patients with out-of-hospital cardiac arrest: a systematic review and meta-analysis. Resuscitation (2015) 96:170–79. doi: 10.1016/j.resuscitation.2015.08.005

31. Kirkegaard H, Søreide E, de Haas I, Pettilä V, Taccone FS, Arus U, et al. Temperature management using the “Esophageal Cooling Device” after cardiac arrest (the COOL study): a feasibility and safety study. Resuscitation (2017) 121:54–61. doi: 10.1016/j.resuscitation.2017.09.021

32. Howes D, Gray SH, Brooks S, Boyd J, Djogovic D, Golan E, et al. Canadian guidelines for the use of targeted temperature management (Therapeutic Hypothermia) after cardiac arrest: a joint statement from The Canadian Association of Emergency Physicians (CAEP), the Canadian Critical Care Society (CCCS), Canadian Neurocritical Care Society (CNCCS), and the Canadian Critical Care Trials Group (CCTTG). Resuscitation (2016) 98:48–63. doi: 10.1016/j.resuscitation.2015.07.052

33. Geocadin RG, Wijdicks E, Armstrong MJ, Damian M, Mayer SA, Ornato JP, et al. Practice guideline summary: reducing brain injury following cardiopulmonary resuscitation: report of the guideline development, dissemination, and implementation subcommittee of the american academy of neurology. Neurology (2017) 88:2149–1 doi: 10.1212/WNL.000000000003966

34. Busl KM, Greer DM. Hypoxic-ischemic brain injury: pathophysiology, neuropathology and mechanisms. Neurorehabilitation (2010) 26:5–13. doi: 10.3233/NRE-2010-0531

35. Westhall E, Rossetti AO, van Rossevelt A, Kjaer TW, Horn J, Ullén S, et al. Standardized EEG interpretation accurately predicts prognosis after cardiac arrest. Neurology (2016) 86:1482–90. doi: 10.1212/WNL.0000000000002462

36. Rittenberger JC, Popescu A, Brenner RP, Guyette FX, Callaway CW. Frequency and timing of nonconvulsive status epilepticus in comatose post-cardiac arrest subjects treated with hypothermia. Neurocrit Care (2012) 16:114–22. doi: 10.1007/s12028-011-9565-0

37. Mani R, Schmitt SE, Mazer M, Mutt ME, Gaisesi DF. The frequency and timing of epileptiform activity on continuous electroencephalogram in comatose post-cardiac arrest syndrome patients treated with therapeutic hypothermia. Resuscitation (2012) 83:840–47. doi: 10.1016/j.resuscitation.2012.02.015

38. Monteiro ML, Taconce FS, Depondt C, Lamanna I, Gaspard N, Ligot N, et al. The prognostic value of 48-h continuous EEG during therapeutic hypothermia after cardiac arrest. Neurocrit Care (2016) 24:152–62. doi: 10.1007/s12028-015-0215-9

39. Alvarez V, Sierra-Marcos A, Oddo M, Rossetti AO. Yield of intermittent versus continuous EEG in comatose survivors of cardiac arrest treated with hypothermia. Critical Care (2013) 17:R90. doi: 10.1186/cc12879

40. Crepeau AZ, Fugate JE, Mandrekar J, White RD, Wijdicks EF, Rabinstein AA, et al. Value analysis of continuous EEG in patients during therapeutic hypothermia after cardiac arrest. Resuscitation (2014) 85:785–89. doi: 10.1016/j.resuscitation.2014.01.019

41. Sandroni C, Cariou A, Cavallaro F, Cronberg T, Friberg H, Hoedemaekers C, et al. Prognostication in comatose survivors of cardiac arrest: an
advocacy statement from the European Resuscitation Council and the European Society of Intensive Care Medicine. Resuscitation (2014) 85:1779–89. doi: 10.1016/j.resuscitation.2014.08.011

50. Crepeau AZ, Rabinstein AA, Fagate JE, Mandrekar J, Wijdicks EF, White RD, et al. Continuous EEG in therapeutic hypothermia after cardiac arrest: prognostic and clinical value. Neurology (2013) 80:339–44. doi: 10.1212/WNL.0b013e318270898d

51. Friberg H, Westhall E, Rosén I, Rundgren M, Nielsen N, Cronberg T. Clinical review: continuous and simplified electroencephalography to monitor brain recovery after cardiac arrest. Crit Care (2013) 17:233. doi: 10.1186/cc12699

52. Synek VM. EEG abnormality grades and subdivisions of prognostic importance in traumatic brain injury. Electroencephalogr Clin Neurophysiol. (1988) 19:160–66.

53. Edgren E, Hedstrand U, Nordin M, Rydin E, Ronquist G. Prediction of poor outcome within the first 3 days of postanoxic coma. Neurology (2016) 87:2963–72. doi: 10.1212/01.wnl.0000492954.66359.7b

54. Bassetti C, Bomio F, Mathis J, Hess CW. Early prognosis in coma after cardiac arrest. Crit Care Med. (1987) 15:820–25. doi: 10.1097/00003246-198709000-00004

55. Berkhoff M, Donati F, Bassetti C. Postanoxic alpha (theta) coma: a review. Neurocrit Care (2005) 2:235–46. doi: 10.1388/NNC.2.2.159

56. Freund B, Kaplan PW. Myoclonus after cardiac arrest: where do we go from here? Epilepsia Curr. (2017) 17:265–72. doi: 10.1111/ecc.12771

57. Zandbergen EG, Hijdra A, Koelman JH, Hart AA, Sanna T, D’Arrigo S, Kuiper M, et al. Predictors of poor neurologic outcome in adult comatose survivors of cardiac arrest. Neurology. (2006) 67:230–3. doi: 10.1212/01.wnl.0000217536.63641.d9

58. Horn J, Tjepkema-Cloostermans MC. Somatosensory evoked potentials in patients with hypoxic-ischemic brain injury. Semin Neurol. (2017) 37:60–5. doi: 10.1055/s-0036-1594252

59. Legriel S, Hilly-Ginoux J, Resche-Rigon M, Merceron S, Pinoteau J, Henry-Lagarrigue M, et al. Automated analysis of background EEG and reactivity during therapeutic hypothermia in comatose patients after cardiac arrest. Clin EEG Neurosci. (2014) 45:6–13. doi: 10.1177/1550059413509616

60. Horn J, Tjepkema-Cloostermans MC. Somatosensory evoked potentials in patients with hypoxic-ischemic brain injury. Semin Neurol. (2017) 37:60–5. doi: 10.1055/s-0036-1594252

61. Wijdicks EF, Hijdra A, Koelman JH, de Haan RJ, Hijdra A, et al. Consensus statement on continuous EEG in critically ill adults and children, part I: indications. J Clin Neurophysiol. (2015) 32:87–95. doi: 10.1097/WNP.000000000000166

62. Sandroni C, D’Arrigo S. Neurologic prognostication: neurologic examination and current guidelines. Semin Neurol. (2017) 37:40–47. doi: 10.1055/s-0036-1593857

63. Legriel S, Hilly-Ginoux J, Resche-Rigon M, Merceron S, Pinoteau J, Henry-Lagarrigue M, et al. Automated analysis of background EEG and reactivity during therapeutic hypothermia in comatose patients after cardiac arrest. Clin EEG Neurosci. (2014) 45:6–13. doi: 10.1177/1550059413509616

64. Vigen S, Vizcaychipi M, Patil S. Role of bispectral index monitoring and burst suppression in prognostication following out-of-hospital cardiac arrest: a systematic review protocol. Syst Rev. (2017) 6:191. doi: 10.1186/s13643-017-0584-6

65. Bouwes A, Binnekade JM, Zandstra DF, Koelman JH, van Schaik IN, Hijdra A, et al. Somatosensory evoked potentials during mild hypothermia treated with hypothermia. Neurology (2010) 37:60–5. doi: 10.1055/s-0036-1594252

66. Weil J, Tjepkema-Cloostermans MC. Somatosensory evoked potentials in patients with hypoxic-ischemic brain injury. Semin Neurol. (2017) 37:60–5. doi: 10.1055/s-0036-1594252

67. Legriel S, Hilly-Ginoux J, Resche-Rigon M, Merceron S, Pinoteau J, Henry-Lagarrigue M, et al. Automated analysis of background EEG and reactivity during therapeutic hypothermia in comatose patients after cardiac arrest. Clin EEG Neurosci. (2014) 45:6–13. doi: 10.1177/1550059413509616

68. Rundgren M, Westhall E, Cronberg T, Rosen I, Friberg H. Continuous amplitude-integrated electroencephalogram predicts outcome in hypothermia-treated cardiac arrest patients. Crit Care Med. (2010) 38:1388–44. doi: 10.1097/CCM.0b013e3181eaa1e7

69. Sivaraju A, Gilmore EJ, Wira CR, Stevens A, Rampal N, Moeller JJ, et al. Prognostication of post-cardiac arrest coma: early clinical and electroencephalographic predictors of outcome. Intens Care Med. (2015) 41:1264–72. doi: 10.1007/s00134-015-3834-x

70. Ko S, Ortega-Gutierrez S, Choi HA, Classen J, Presciutti M, Schmidt JM, et al. Status epilepticus-induced hyperemia and brain tissue hypoxia after cardiac arrest. Arch Neurol. (2011) 68:1323–6. doi: 10.1001/archneurol.2011.240

71. Sehlhamer JC, Baldwin ME, Callaway CW, Popescu A. Malignant EEG patterns in cardiac arrest patients treated with targeted temperature management who survive to hospital discharge. Resuscitation (2015) 90:127–32. doi: 10.1016/j.resuscitation.2015.03.005

72. Edgren E, Hedstrand U, Nordin M, Rydin E, Ronquist G. Prediction of poor outcome within the first 3 days of postanoxic coma. Neurology (2016) 87:2963–72. doi: 10.1212/01.wnl.0000492954.66359.7b
hypothermia in postcardiac arrest patients. Ther Hypothermia Temp Manag. (2016) 6:189–93. doi: 10.1089/ther.2016.0009
123. International Cardiac Arrest Registry (INTCAR). International Cardiac Arrest Registry. (2012). Available online at: http://www.intcar.org/
124. ClinicalTrials.gov. Identifier NCT03261089, Multimodal Outcome CHAracterization in Comatose Cardiac Arrest Patients Registry and Tissue Repository (MOCHA). (2017). Available online at: https://clinicaltrials.gov/ct2/show/NCT03261089.
125. Cronberg T, Kuiper M. Withdrawal of life-sustaining therapy after cardiac arrest. Semin Neurol. (2017) 37:81–7. doi: 10.1055/s-0036-1595814
126. Fendler TJ, Spertus JA, Kennedy KF, Chen LM, Perman SM, Chan PS, et al. Alignment of do-not-resuscitate status with patients' likelihood of favorable neurological survival after in-hospital cardiac arrest. JAMA (2015) 314:1264–71. doi: 10.1001/jama.2015.11069

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer CD and handling Editor declared their shared affiliation at the time of the review.

Copyright © 2018 Nguyen, Alreshaid, Poblete, Konye, Marehbian and Sung. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.